<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943409</url>
  </required_header>
  <id_info>
    <org_study_id>CAPCR ID: 13-5807</org_study_id>
    <nct_id>NCT01943409</nct_id>
  </id_info>
  <brief_title>Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils</brief_title>
  <official_title>Parenteral Nutrition in Hospitalized Patients: Comparison of Two Commercially Available Lipid Emulsions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johane Allard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous nutrition is an important therapy for the recovery of many patients. It is
      indicated when the patients cannot take food by mouth or use their intestines for feeding. It
      is important to indicate it in the appropriate setting because it's not free of complications
      and is a costly treatment. Some of the complications are: elevated blood sugar or lipids,
      elevated liver function tests, infection of the catheter or device used to administer
      intravenous nutrition. Intravenous nutrition is composed by proteins, lipids, carbohydrates
      (sugar in the form of glucose) and vitamins. Until recently, Intralipid, a soybean oil-based
      lipid emulsion was the only lipid available in Canada for this kind of nutrition. Since 2010,
      a new lipid emulsion (ClinOleic) based on olive-oil has been approved by Health Canada for
      use in intravenous nutrition. There is an increasing need for hospitals to evaluate the
      quality of intravenous nutrition administered to hospitalized patients in terms of: assessing
      indications, prescription, complications, clinical results and costs. The objective of this
      study is to determine if intravenous nutrition prescribed in hospitalized patients is
      indicated following existing guidelines in terms of timing of nutrition support,
      prescription, monitoring and whether it is associated with complications. In addition, length
      of stay and mortality will be assessed. Also, we will evaluate nutritional, infectious and
      inflammatory parameters in patients receiving soybean oil-based lipid emulsion (Intralipid)
      compared to those of patients receiving olive oil-based lipid emulsion (ClinOleic).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Until recently, Intralipid, a soybean oil-based lipid emulsion, has been the only available
      lipid for intravenous use in Canada. In 2010, ClinOleic, a new, predominantly olive oil based
      emulsion, has been approved by Health Canada as an alternative lipid.

      There is an increasing need for hospitals to do quality-assurance studies for in-patient
      parenteral nutrition (PN) to assess indications, PN prescription, complications, clinical
      outcomes and costs. The only in-patient population that is well studied is the intensive care
      unit (ICU) population. Several meta-analyses showed that PN was associated with higher
      infection rate, longer length of stay and higher mortality when compared with enteral
      nutrition. Results from these and other studies were the basis for the Canadian ICU
      Guidelines.

      The aim of this study is to determine if PN prescribed in in-patients is indicated,
      appropriately following existing guidelines in terms of timing of nutrition support,
      prescription and monitoring and, whether it is associated with complications. In addition,
      clinical outcomes such as length of stay and mortality will be assessed. Also, we will
      evaluate metabolic, nutritional, infectious and inflammatory parameters in patients receiving
      soybean oil-based lipid emulsion compared to those of patients receiving olive oil-based
      lipid emulsion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prealbumin</measure>
    <time_frame>at baseline (day 0) and day 10</time_frame>
    <description>prealbumin is an hepatic protein that is used in the diagnosis of malnutrition. It has a short half-life so any changes in nutritional status can rapidly be represented by prealbumin levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <description>Length of stay in the hospital and ICU will be recorded. We will record how many days it took,since admission to the hospital, for the patient to be discharged. This is an expected average of 4 weeks of length of stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>participantes will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <description>We will follow the patients from the day of admission until the day of discharge and record the mortality, if applicable. The expected average of hospital stay is 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Baseline(day 0), day 10 and last day of PN (expected after an average of 3 weeks)</time_frame>
    <description>We will measure weight before, at day 10 and after PN to calculate the BMI at this different points. The last day of PN is whenever the patient is taken off PN. This can vary considerably from patient to patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>until one week post-PN (averag expected 4 weeks)</time_frame>
    <description>we will record the infections the patients develop during PN until one week after PN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hand-grip strength</measure>
    <time_frame>at baseline (day 0) and day 10 of PN</time_frame>
    <description>We will measure hand grip strength at baseline (day0) and at day 10 of PN. This is a test that measures the strength of the hand and forearm muscles and is often used as a general test of strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mid-arm circumference</measure>
    <time_frame>at baseline (day0) and day 10</time_frame>
    <description>This is a rough indicator of body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective global assessment (SGA)</measure>
    <time_frame>at baseline (day 0) and day 10</time_frame>
    <description>is a bedside method that assesses the risk of malnutrition and identifies which patient will benefit best from nutrition support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic days</measure>
    <time_frame>until one week post PN</time_frame>
    <description>we will record antibiotic days from the start of PN until one week after PN is discontinued</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high sensitivity C-reactive Protein (hs-CRP)</measure>
    <time_frame>Baseline (day 0) and day 10</time_frame>
    <description>hs-CRP is a marker of inflammation, we will measure this parameter at baseline and after 10 days of PN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell fatty acid composition</measure>
    <time_frame>Baseline (day 0) and day 10</time_frame>
    <description>Red blood cell fatty acid composition, particularly the essential fatty acids (linoleic acid and alpha-linolenic acid) will be measured to assess presence/absence of essential fatty acid deficiency</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Obstruction</condition>
  <condition>Cancer</condition>
  <condition>Ileus</condition>
  <condition>Malnutrition</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Intralipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Intralipid, which is the standard lipid emulsion used in the hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ClinOleic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that are randomized to receive ClinOleic as a lipid emulsion in their PN, instead of Intralipid. ClinOleic is approved by Health Canada. The amount of calories from the lipid emulsion will be equivalent in the standard of care group and in the ClinOleic group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>soybean oil-based lipid emulsion</description>
    <arm_group_label>Intralipid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ClinOleic</intervention_name>
    <description>olive oil-based lipid emulsion</description>
    <arm_group_label>ClinOleic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years or older

               -  Patients with PN during their hospitalization

               -  Patients hospitalized in medical, surgical or ICU wards

               -  Signed informed consent either from the patient, their legally authorized
                  representative or a direct family member

        Exclusion Criteria:

          -  â€¢ Patients without PN during their hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johane P Allard, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sultan Alenezi, MScAHN</last_name>
    <phone>+1-416-340-4413</phone>
    <email>sultan.alenezi@uhnresearch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica L Ponta, MD</last_name>
    <phone>+1-416-340-4413</phone>
    <email>monica.ponta@uhnresearch.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sultan Alenezi, MScAHN</last_name>
      <phone>+1-416-340-4413</phone>
      <email>sultan.alenezi@uhnresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Monica L Ponta, MD</last_name>
      <phone>+1-416-340-4413</phone>
      <email>monica.ponta@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Johane P Allard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Johane Allard</investigator_full_name>
    <investigator_title>Professor of Medicine, Director-Division of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Parenteral nutrition</keyword>
  <keyword>lipid emulsion</keyword>
  <keyword>Intralipid</keyword>
  <keyword>ClinOleic</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Infection</keyword>
  <keyword>Bloodstream Infection</keyword>
  <keyword>length of stay</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

